ALYREF and non-small cell lung carcinoma: A mechanistic study revealed that LINC02159 combined with ALYREF to enhance the stability of YAP1 mRNA through m5C modification, which led to the upregulation of YAP1 expression and activation of the Hippo and β-catenin signaling pathways, thereby promoting the progression of NSCLC [20].